Effect of <i>Enteromorpha</i> Polysaccharide on Intestinal Bacteria and Short Chain Fatty Acids in Obese Golden Hamsters

HUANG Shiying; CHEN Jiedong; HAN Mengyuan; XU Caihong; GUO Fuchuan

doi:10.13386/j.issn1002-0306.2022030170

Volume 44 Issue 3

Jan. 2023

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2023 > 44(3): 381-390. > DOI: 10.13386/j.issn1002-0306.2022030170

HUANG Shiying, CHEN Jiedong, HAN Mengyuan, et al. Effect of Enteromorpha Polysaccharide on Intestinal Bacteria and Short Chain Fatty Acids in Obese Golden Hamsters[J]. Science and Technology of Food Industry, 2023, 44(3): 381−390. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022030170.

Citation:

PDF (3768 KB)

Effect of Enteromorpha Polysaccharide on Intestinal Bacteria and Short Chain Fatty Acids in Obese Golden Hamsters

1.
School of Public Health, Fujian Medical University, Fuzhou 350122, China
2.
Fujian Maternity and Child Health Hospital, Fuzhou 350001, China

More Information

Received Date: March 14, 2022
Available Online: December 03, 2022

Graphical Abstract

Abstract

Abstract

Objective: To investigate the effect of Enteromorpha polysaccharide (EP) on blood lipids and intestinal bacteria in obese golden hamsters. Method: Forty male golden hamsters were randomly divided into four groups, including control group (ND), model group (HFD), low-dose EP group (LEP, 300 mg/kg·BW), and high-dose EP group (HEP, 450 mg/kg·BW). The ND group was fed an ordinary diet, while the other three groups were given a high-fat diet. Among the high-fat diet groups, the LEP and HEP groups were continuously administered EP aqueous solution intragastrically. Twelve weeks later, the serum lipid levels were evaluated, the diversity and structural changes in the gut bacteria were examined using 16S rDNA sequencing, and the short-chain fatty acid concentration in faeces was examined using a gas chromatography flame ionisation detector (GC-FID). Results: After 12 weeks, the body weight, serum total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) of hamsters in the HFD group were considerably higher than those in the ND group (P<0.05). In contrast, high-dose EP treatment led to a significant decrease in serum TC, TG, LDL-C, and alanine aminotransferase (ALT) levels (P<0.05). Results of 16S rDNA sequencing revealed that at the phylum level the proportion of Firmicutes/Bacteroidetes was substantially higher in the HFD group than in the ND group (P<0.05). However, the level of Firmicutes/Bacteroidetes was much lower in the HEP group, compared to the HFD group (P<0.05). At the genus level, Eubacterium_coprostanoligenes_group and Lachnospiraceae UCG-006 were more abundant in the HFD group than in the ND group (P<0.05). Following high-dose EP intervention, the relative abundance of Eubacterium_coprostanoligenes_group and Lachnospiraceae_UCG-006 fell significantly, compared to the HFD group (P<0.05). Additionally, a high-fat diet feeding resulted in a decrease in the content of short-chain fatty acids in faeces, while high-dose EP intervention significantly increased the short-chain fatty acid content in faeces (P<0.05). Conclusion: The administration of EP alleviates the metabolic disorders of obese golden hamsters fed with a high-fat diet by moderating the composition of intestinal bacteria and enhancing the production of short-chain fatty acids.
- Enteromorpha polysaccharides,
- high-fat diet,
- gut microbiota,
- short-chain fatty acids

FullText(HTML)

References (34)

References

[1]	NITTARI G, SCURI S, PETRELLI F, et al. Fighting obesity in children from European World Health Organization Member States. Epidemiological data, medical-social aspects, and prevention programs[J]. Clin Ter,2019,170(3):e223−e230.
[2]	PAN X F, WANG L, PAN A. Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol,2021,9(6):373−392. doi: 10.1016/S2213-8587(21)00045-0
[3]	LEE S J, SHIN S W. Mechanisms, pathophysiology, and management of obesity[J]. N Engl J Med,2017,376(15):1491−1492.
[4]	LIU B N, LIU X T, LIANG Z H, et al. Gut microbiota in obesity[J]. World Journal of Gastroenterology,2021,27(25):3837−3850. doi: 10.3748/wjg.v27.i25.3837
[5]	TURNBAUGH P J, LEY R E, MAHOWALD M A, et al. An obesity-associated gut microbiome with increased capacity for energy harvest[J]. Nature,2006,444(7122):1027−1031. doi: 10.1038/nature05414
[6]	高鑫, 山珊, 曾德永, 等. 石莼属绿藻多糖的生物活性研究进展[J]. 食品工业科技,2021,42(2):364−369. [GAO X, SHAN S, ZENG D Y, et al. Research progress on biological activity of ulvan[J]. Science and Technology of Food Industry,2021,42(2):364−369. doi: 10.13386/j.issn1002-0306.2020040007
[7]	TENG Z, QIAN L, ZHOU Y. Hypolipidemic activity of the polysaccharides from Enteromorpha prolifera[J]. Int J Biol Macromol,2013,62:254−256. doi: 10.1016/j.ijbiomac.2013.09.010
[8]	SHANG Q, WANG Y, PAN L, et al. Dietary polysaccharide from Enteromorpha clathrata modulates gut microbiota and promotes the growth of Akkermansia muciniphila, Bifidobacterium spp. and Lactobacillus spp.[J]. Mar Drugs,2018,16(5):167. doi: 10.3390/md16050167
[9]	REN X, LIU L, GAMALLAT Y, et al. Enteromorpha and polysaccharides from Enteromorpha ameliorate loperamide-induced constipation in mice[J]. Biomed Pharmacother,2017,96:1075−1081. doi: 10.1016/j.biopha.2017.11.119
[10]	KONG Q, DONG S Y, GAO J, et al. In vitro fermentation of sulfated polysaccharides from E. prolifera and L. japonica by human fecal microbiota[J]. Int J Biol Macromol,2016,91:867−871. doi: 10.1016/j.ijbiomac.2016.06.036
[11]	张宵, 刘杨, 滕博, 等. 基于肠道菌群的海藻多糖对部分疾病影响的研究进展[J]. 食品工业科技,2021,42(18):421−426. [ZHANG X, LIU Y, TENG B, et al. Research progress of the effects of seaweed polysaccharides on some diseases based on intestinal flora[J]. Science and Technology of Food Industry,2021,42(18):421−426. doi: 10.13386/j.issn1002-0306.2020080239
[12]	CABRAL L, PERSINOTI G F, PAIXAO D A A, et al. Gut microbiome of the largest living rodent harbors unprecedented enzymatic systems to degrade plant polysaccharides[J]. Nature Communications, 2022, 13(1): 629-629.
[13]	LITVAK Y, BYNDLOSS M X, TSOLIS R M, et al. Dysbiotic Proteobacteria expansion: A microbial signature of epithelial dysfunction[J]. Curr Opin Microbiol,2017,39:1−6. doi: 10.1016/j.mib.2017.07.003
[14]	GOMEZ-ARANGO L F, BARRETT H L, MCINTYRE H D, et al. Connections between the gut microbiome and metabolic hormones in early pregnancy in overweight and obese women[J]. Diabetes,2016,65(8):2214−2223. doi: 10.2337/db16-0278
[15]	VOJINOVIC D, RADJABZADEH D, KURILSHIKOV A, et al. Relationship between gut microbiota and circulating metabolites in population-based cohorts[J]. Nature Communications,2019,10(1):5813. doi: 10.1038/s41467-019-13721-1
[16]	TUN H M, BRIDGMAN S L, CHARI R, et al. Roles of birth mode and infant gut microbiota in intergenerational transmission of overweight and obesity from mother to offspring[J]. Jama Pediatr,2018,172(4):368−377. doi: 10.1001/jamapediatrics.2017.5535
[17]	ZHAO L, ZHANG Q, MA W N, et al. A combination of quercetin and resveratrol reduces obesity in high-fat diet-fed rats by modulation of gut microbiota[J]. Food Funct,2017,8(12):4644−4656. doi: 10.1039/C7FO01383C
[18]	WEI W, JIANG W B, TIAN Z, et al. Fecal g. Streptococcus and g. Eubacterium_coprostanoligenes_group combined with sphingosine to modulate the serum dyslipidemia in high-fat diet mice[J]. Clin Nutr,2021,40(6):4234−4245. doi: 10.1016/j.clnu.2021.01.031
[19]	PETERSEN C, BELL R, KIAG K A, et al. T cell-mediated regulation of the microbiota protects against obesity[J]. Science,2019,365:340.
[20]	PIDCOCK S E, SKVORTSOV T, SANTOS F G, et al. Phylogenetic systematics of Butyrivibrio and Pseudobutyrivibrio genomes illustrate vast taxonomic diversity, open genomes and an abundance of carbohydrate-active enzyme family isoforms[J]. Microb Genomics,2021,7(10):000638.
[21]	CANI P D. Microbiota and metabolites in metabolic diseases[J]. Nat Rev Endocrinol,2019,15(2):69−70. doi: 10.1038/s41574-018-0143-9
[22]	DENG X L, MA J, SONG M T, et al. Effects of products designed to modulate the gut microbiota on hyperlipidaemia[J]. Eur J Nutr,2019,58(7):2713−2729. doi: 10.1007/s00394-018-1821-z
[23]	SCHOELER M, CAESAR R J R I E, DISORDERS M. Dietary lipids, gut microbiota and lipid metabolism[J]. 2019, 20(4): 461-472.
[24]	FU J, BONDER M J, CENIT M C, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids[J]. Circulation Research,2015,117(9):817−824. doi: 10.1161/CIRCRESAHA.115.306807
[25]	MESLIER V, LAIOLA M, ROAGER H M, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake[J]. Gut,2020,69(7):1258−1268. doi: 10.1136/gutjnl-2019-320438
[26]	MAKKI K, DEEHAN E C, WALTER J, et al. The impact of dietary fiber on gut microbiota in host health and disease[J]. Cell Host Microbe,2018,23(6):705−715. doi: 10.1016/j.chom.2018.05.012
[27]	KLANCIC T, REIMER R A. Gut microbiota and obesity: Impact of antibiotics and prebiotics and potential for musculoskeletal health[J]. J Sport Health Sci,2020,9(2):110−118. doi: 10.1016/j.jshs.2019.04.004
[28]	MO X, SUN Y, LIANG X, et al. Insoluble yeast β-glucan attenuates high-fat diet-induced obesity by regulating gut microbiota and its metabolites[J]. 2022, 281: 119046.
[29]	XU S, AWEYA J, LI N, et al. Microbial catabolism of porphyra haitanensis polysaccharides by human gut microbiota[J]. 2019, 289: 177-186.
[30]	TANG C, DING R, SUN J, et al. The impacts of natural polysaccharides on intestinal microbiota and immune response-A review[J]. 2019, 10(5): 2290-2312.
[31]	NGUYEN S, KIM J, GUEVARRA R, et al. Laminarin favorably modulates gut microbiota in mice fed a high-fat diet[J]. Food & Function,2016,7(10):4193−4201.
[32]	CHEN Y F, JIN L, LI Y H, et al. Bamboo-shaving polysaccharide protects against high-diet induced obesity and modulates the gut microbiota of mice[J]. Journal of Functional Foods,2018,49:20−31. doi: 10.1016/j.jff.2018.08.015
[33]	LI S Y, WANG L N, LIU B, et al. Unsaturated alginate oligosaccharides attenuated obesity-related metabolic abnormalities by modulating gut microbiota in high-fat-diet mice[J]. Food Funct,2020,11(5):4773−4784. doi: 10.1039/C9FO02857A
[34]	LAGKOUVARDOS I, LESKER T R, HITCH T C A, et al. Sequence and cultivation study of Muribaculaceae reveals novel species, host preference, and functional potential of this yet undescribed family[J]. Microbiome,2019,7(1):28. doi: 10.1186/s40168-019-0637-2

Supplements (0)

Cited By

Cited by

Periodical cited type(13)

1.	沙琦，孙未一，范兴丽. 肠道菌群代谢物与抑郁症发病机制关系的研究. 浙江医学教育. 2025(01): 60-64 .
2.	姜浩，赵杰，王铁云. “微生物-肠-脑轴”理论下述中医治疗郁症的研究进展. 中医临床研究. 2024(03): 27-31 .
3.	姜浩，赵杰，王铁云. “微生物-肠-脑轴”理论下述中医治疗郁症的研究进展. 中医临床研究. 2024(09): 135-138 .
4.	张红娟，王崴，高敏，安邦，范雅娟，贾敏，李强. 抑郁症患者血清短链脂肪酸水平与症状及生化指标的相关性. 山西医科大学学报. 2024(06): 777-781 .
5.	康艳宝，赵龙友. 抗抑郁药联合肠道菌群调节剂治疗抑郁症疗效分析. 中国基层医药. 2024(08): 1144-1148 .
6.	徐曼华，李平，何兰英，高丽梅. 老年抑郁症患者应用微生态制剂辅助认知行为干预的效果. 国际精神病学杂志. 2024(06): 1784-1787 .
7.	赵佳，沈馨，刘红霞，郭艳荣，高广琦，孙志宏. 益生菌缓解亚健康相关症状的研究进展. 中国食品学报. 2024(12): 432-440 .
8.	胡科，张同同，张凯，王国强. 首发抑郁症患者肠道菌群多样性与抑郁症状的相关性分析. 微生物学通报. 2023(03): 1040-1051 .
9.	任煜，张童，李宁，裴环，赵童，袁嘉丽. 基于“脾与小肠相通”理论探讨脾-肠-肠道微生态治疗抑郁症. 世界中西医结合杂志. 2023(05): 1031-1035 .
10.	吴振宁，王琦，秦雪梅，田俊生. 肠道菌群及其代谢产物在中药治疗抑郁症中的研究进展. 中草药. 2023(14): 4713-4721 .
11.	李秋颖，冯静，刘婕，杨蓉蓉，骆华正，蔡伦，韦理萍. 肠道菌群在抑郁症发病机制及中医药治疗中研究进展. 辽宁中医药大学学报. 2023(12): 96-101 .
12.	袁霞红，刘林. 肠道菌群调节抑郁症机制及中医药防治研究进展. 中华中医药学刊. 2022(09): 167-170 .
13.	徐慧慧，陈煦，赵芳，毛若曦，王文利，程智美，张雅丽. 饮食结构、营养成分对抑郁症的影响研究进展. 食品科学. 2022(23): 346-355 .